A distressed pharmaceutical manufacturing company with nationwide presence, currently under the Corporate Insolvency Resolution Process (CIRP). The company owns six facilities across India and was last engaged in the production of APIs and intermediates for regulated and unregulated markets. The asset is available under the IBC process and offers an opportunity to revive a previously revenue-generating business with multi-site infrastructure.
Location:
Facilities across Maharashtra, Telangana, and Haryana
Aquisition:
Through CIRP
Manufacturing Focus:
Active Pharmaceutical Ingredients (APIs) and intermediates for both domestic and global markets
Ownership & Governance:
Public limited company with suspended board of directors; governed by Resolution Professional
Company was engaged in the manufacturing and sale of a wide range of APIs and intermediates across therapeutic categories such as:
Its offerings catered to both innovators and generic drug companies in India and international markets, including regulated markets.
Manufacturing Units:
Core Capabilities:
Position in Value Chain:
Manufacturer of intermediates and APIs for pharmaceutical supply chains, with offerings that served global and domestic clients.
Company represents a significant investment opportunity for pharma strategics or PE-backed consolidators seeking:
